Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 222-492-8 | CAS number: 3495-36-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From July 23, 2013 to January 09, 2013
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 013
- Report date:
- 2013
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Deviations:
- yes
- Remarks:
- No significant deviations to study plan which affected the outcome of the study.
- GLP compliance:
- yes (incl. QA statement)
Test material
- Reference substance name:
- Caesium hydroxide monohydrate
- Cas Number:
- 35103-79-8
- Molecular formula:
- CsOH*H2O
- IUPAC Name:
- Caesium hydroxide monohydrate
- Test material form:
- solid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Hsd.Brl.Han: of Wistar origin
- Details on test animals or test system and environmental conditions:
- - Source: Charles River (Europe) Laboratories Inc. Toxi-Coop Zrt. 1103 Budapest, Cserkesz u. 90. Hungary
- Age: Females: Young adult and nulliparous females, 11-12 weeks of age at start of the mating period
Males: experienced males used in the developmental DRF study (Study no.: 559.410.3533), 23-24 weeks of age at start of the mating period
- Bodyweight: The group averages of the body weight were as similar as possible on the first day of gestation
- Housing:
Before mating: 1-3 females /cage 1-2 males/cage
Mating: 1 male and 1-3 females / cage
During gestation: 2-3 sperm positive females /cage, if not possible 1 sperm positive female per cage
- Cage type:
Type II polypropylene/polycarbonate
- Bedding:
Lignocel Hygienic Animal Bedding produced by J. Rettenmaier & Söhne GmbH+Co.KG (D-73494 Rosenberg, Holzmühle 1, Germany). Details of bedding quality were reported (Appendix XXIII).
- Light:
12 hours daily, from 6.00 a.m. to 6.00 p.m.
- Temperature:
21-22 °C
- Relative humidity:
40 - 54 %
- Ventilation:
8-12 air exchanges/hour by central air-condition system.
The temperature and relative humidity were checked and recorded once daily during the study. Any deviations were documented.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test item was formulated in the vehicle (distilled water) in concentrations of 1, 4, and 15 mg/mL.
Formulations were prepared daily to weekly. Due to the corrosive properties of the test item, the pH value of the formulations was adjusted to pH 7-9 with HCl prior to gavage administration. The suitability of the chosen vehicle for the test item at the intended concentrations was analytically verified up front. A sufficient stability and homogeneity in the chosen vehicle were verified over the range of relevant concentrations at the appropriate frequency of preparation. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Analytical control (concentration, homogeneity) of dosing solutions was performed twice during the treatment period. The Cesiumhydroxidmonohydrat 99.95 concentrations in the samples were found to be 94 – 95 % in comparison to the nominal values.
- Details on mating procedure:
- The females were paired to males in the mornings for two to four hours (one male: one to three females) until the number of sperm positive females / group achieved at least twenty four. Vaginal smears were prepared from each female, stained with 1 % aqueous methylene blue solution and examined for presence of sperm and for estrus cycle stage.
The day of mating was regarded as day 0 of pregnancy (vaginal plug and/or sperm in the vaginal smear). Sperm positive females were separated and caged in groups of 2 to 3 animals (if not possible one female per cage). Caging of the females individually was avoided except in case of three dams. - Duration of treatment / exposure:
- The sperm positive females were treated from gestational day 5 to 19.
- Frequency of treatment:
- The test item was administered in a single dose by oral gavage (stomach tube) on a 7 days/week basis every day at similar time.
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day (actual dose received)
- Remarks:
- Controls
- Dose / conc.:
- 10 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 40 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 150 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 25 females for the controls, 27 females for the treated groups.
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Based on the results of a 28 day oral toxicity study
Examinations
- Maternal examinations:
- CLINICAL EXAMINATIONS
General clinical observations of the females were made once a day from day 0 up to day 19 which were performed after treatment at approximately the same time during the treatment period, considering the peak period of anticipated effects after dosing. Individual observation included the check of behavior and general condition.
Observations for signs of morbidity and mortality were made twice daily, at the beginning of the working period and in the afternoon.
BODYWEIGHT
The body weight of the male animals was not measured.
The body weight of all female rats was measured at least once in the pre-mating period, but was not statistically evaluated. Body weight of sperm positive females was measured on gestation days 0, 3, 5, 8, 11, 14, 17 and 20 (accuracy of 1 g).
The corrected body weight was calculated for day 20 of pregnancy (body weight on day 20 minus the weight of the gravid uterus).
FOOD CONSUMPTION
Food consumption was determined between gestation days 0 to 3, 3 to 5, 5 to 8, 8 to 11, 11 to 14, 14 to 17 and 17 to 20 by weighing the diet at the start of each measurement period and by re-weighing the non-consumed diet at the end of the respective period (accuracy: 1 g).
PLACENTAL SIGNS
All sperm positive animals were examined for vaginal bleeding (placental sign of gestation) on the 13th gestational day. If negative on day 13, the examination was repeated on day 14 of gestation. - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes - Fetal examinations:
- - External examinations: Yes: [all per litter]
- Soft tissue examinations: Yes: [half per litter]
- Skeletal examinations: Yes: [half per litter]
- Head examinations: Yes: [half per litter] - Statistics:
- The statistical evaluation of data was performed with the program package SPSS PC+4.0.
The homogeneity of variance between groups was checked by Bartlett’s homogeneity of variance test.
Where no significant heterogeneity was detected a one-way analysis of variance (ANOVA) was carried out. If the obtained result was significant Duncan’s Multiple Range test was used to access the significance of inter-group differences. If a significance was the result of the Bartlett’s test, the Kruskal-Wallis analysis of variance was used and the inter-group comparisons were performed using Mann-Whitney U-test. - Historical control data:
- Yes
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- There were no clinical signs or treatment related necropsy findings recorded for the dams.
- Mortality:
- no mortality observed
- Description (incidence):
- None of the pregnant females died in the course of the study before scheduled necropsy.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- A statistically significant reduction in the food consumption was to see in the mid and high dose group (40 and 150 mg/kg bw/day) from gestational day 14 up to necropsy if compared to the control. This reduction in the food consumption was observed in association with a statistically significantly lower body weight gain in the high dose group noted during the last three days of the study and during the whole in-life phase. Corrected body weight gain in the mid and high dose groups was also statistically significantly reduced. These findings were attributed to an effect of the test substance.
The slightly reduced food consumption of the dams which was statistically significant in the mid dose group (40 mg/kg bw/day) between days 11 to 14 (without a dose response) and the slightly lower food consumption of the dams in the low dose group (10 mg/kg bw/day) associated with no changes in the body weight parameters and were considered to be incidental.
There were no significant differences in the body weight and body weight gain of the dams in the low and mid dose groups (0 and 40 mg/kg bw/day). - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- not examined
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- not examined
Maternal developmental toxicity
- Number of abortions:
- not examined
- Pre- and post-implantation loss:
- no effects observed
- Description (incidence and severity):
- There was no effect related to the administration of the test substance in the preimplantation loss, intrauterine mortality of the conceptuses, the number of implantations, viable fetuses and their sex distribution.
- Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- not examined
- Description (incidence and severity):
- Migrated Data from removed field(s)
Field "Effects on pregnancy duration" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsMaternalAnimals.MaternalDevelopmentalToxicity.EffectsOnPregnancyDuration): not examined - Changes in number of pregnant:
- not examined
- Other effects:
- not examined
Effect levels (maternal animals)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 10 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- body weight and weight gain
- Remarks on result:
- other:
- Remarks:
- equivalent to 12 mg cesium formate monohydrate/kg bw/day
Maternal abnormalities
- Key result
- Abnormalities:
- no effects observed
Results (fetuses)
- Fetal body weight changes:
- no effects observed
- Description (incidence and severity):
- Migrated Data from removed field(s)
Field "Fetal/pup body weight changes" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsFetuses.FetalPupBodyWeightChanges): no effects observed - Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- not examined
- Changes in postnatal survival:
- not examined
- External malformations:
- no effects observed
- Skeletal malformations:
- no effects observed
- Visceral malformations:
- no effects observed
- Other effects:
- no effects observed
Effect levels (fetuses)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 150 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no effects
- Remarks on result:
- other:
- Remarks:
- equivalent to 175 mg cesium formate monohydrate/kg bw/day
Fetal abnormalities
- Key result
- Abnormalities:
- no effects observed
Overall developmental toxicity
- Key result
- Developmental effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- Under the study conditions, the NOAEL for maternal toxicity was determined to be 10 mg/kg bw/day (equivalent to 12 mg cesium formate monohydrate/kg bw/day) and the NOAEL for developmental toxicity was 150 mg/kg bw/day (equivalent to 175 mg cesium formate monohydrate/kg bw/day).
- Executive summary:
A study was conducted to determine the prenatal developmental toxicity of the read across substance cesium hydroxide monohydrate 99.95 according to OECD Guideline 414, in compliance with GLP. Groups of 27 sperm-positive female Hsd. Brl. Han: WISTAR rats were treated with the test substance by oral administration daily at 10, 40 and 150 mg/kg bw/day from Day 5 up to and including Day 19 post coitum. A control group of 25 sperm positive females was included and the animals were given the vehicle distilled water. The treatment volume was 10 mL/kg bw. During the study, mortality was checked for and clinical observations were performed. Body weight and food consumption of the dams were also recorded. The day when sperm was detected in the vaginal smear was regarded as Day 0 of gestation. A Caesarean section and gross pathology were performed on Gestational Day 20. The number of implantations, early and late resorptions, live and dead fetuses in each uterine horn and the number of corpora lutea were recorded. Each fetus was weighed and examined for sex and gross external abnormalities. The placentas were weighed and examined externally. About half of each litter was preserved for visceral examination and the other half of the litters were preserved for skeletal evaluation. At visceral examination the bodies were micro dissected by means of a dissecting microscope. The heads were examined by Wilson's free-hand razor blade method. After cartilage-bone staining the skeletons were examined by means of a dissecting microscope. All abnormalities found during the fetal examinations were recorded.None of the pregnant females died in the course of the study before scheduled necropsy. There were no clinical signs or treatment related necropsy findings recorded for the dams. A statistically significant reduction in the food consumption was seen at 40 and 150 mg/kg bw/day from Gestational Day 14 up to necropsy compared to the control. This reduction in the food consumption was observed in association with a statistically significantly lower body weight gain in the high dose group noted during the last three days of the study and during the whole in-life phase. Corrected body weight gain in the mid and high dose groups was also statistically significantly reduced. These findings were attributed to an effect of the test substance. The slightly reduced food consumption of the dams which was statistically significant at 40 mg/kg bw/day between Days 11 to 14 (without a dose response) and the slightly lower food consumption of the dams at 10 mg/kg bw/day associated with no changes in the body weight parameters and were considered to be incidental. There were no significant differences in the body weight and body weight gain of the dams at 0 and 40 mg/kg bw/day.There was no effect related to the administration of the test substance in the preimplantation loss, intrauterine mortality of the conceptuses, the number of implantations, viable fetuses and their sex distribution. The mean fetal weight, placental and relative placental weight were similar across the control and test substance treated groups. The distribution of external, visceral and skeletal variations was homogenous among the experimental groups. There were no malformations found during external and visceral evaluation of the fetuses and there were no significant differences in the skeletal malformations if compared to the control. Under the study conditions, the NOAEL for maternal toxicity was determined to be 10 mg/kg bw/day (equivalent to 12 mg cesium formate monohydrate/kg bw/day) and the NOAEL for developmental toxicity was 150 mg/kg bw/day (equivalent to 175 mg cesium formate monohydrate/kg bw/day) (Toxi-COOP, 2013).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.